Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 8.16
LGND's Cash to Debt is ranked higher than
81% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. LGND: 8.16 )
LGND' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 8.16

Equity to Asset 0.64
LGND's Equity to Asset is ranked higher than
73% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. LGND: 0.64 )
LGND' s 10-Year Equity to Asset Range
Min: -0.83   Max: 0.68
Current: 0.64

-0.83
0.68
Interest Coverage No Debt
LGND's Interest Coverage is ranked higher than
93% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. LGND: No Debt )
LGND' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 9.06
M-Score: -0.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 29.38
LGND's Operating margin (%) is ranked higher than
97% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. LGND: 29.38 )
LGND' s 10-Year Operating margin (%) Range
Min: -1963.29   Max: 30.51
Current: 29.38

-1963.29
30.51
Net-margin (%) 13.85
LGND's Net-margin (%) is ranked higher than
87% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. LGND: 13.85 )
LGND' s 10-Year Net-margin (%) Range
Min: -798.16   Max: 2184.64
Current: 13.85

-798.16
2184.64
ROE (%) 14.31
LGND's ROE (%) is ranked higher than
89% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. LGND: 14.31 )
LGND' s 10-Year ROE (%) Range
Min: -1046.55   Max: 997.71
Current: 14.31

-1046.55
997.71
ROA (%) 7.36
LGND's ROA (%) is ranked higher than
85% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. LGND: 7.36 )
LGND' s 10-Year ROA (%) Range
Min: -95.66   Max: 112.83
Current: 7.36

-95.66
112.83
ROC (Joel Greenblatt) (%) 2091.37
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. LGND: 2091.37 )
LGND' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1430.01   Max: 1805.8
Current: 2091.37

-1430.01
1805.8
Revenue Growth (%) 25.30
LGND's Revenue Growth (%) is ranked higher than
89% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. LGND: 25.30 )
LGND' s 10-Year Revenue Growth (%) Range
Min: -64.8   Max: 90.1
Current: 25.3

-64.8
90.1
» LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

LGND Guru Trades in Q3 2013

Joel Greenblatt 6,136 sh (New)
RS Investment Management 591,370 sh (New)
Paul Tudor Jones 11,700 sh (New)
Steven Cohen Sold Out
» More
Q4 2013

LGND Guru Trades in Q4 2013

Joel Greenblatt 13,803 sh (+124.95%)
RS Investment Management 1,315,098 sh (+122.38%)
Paul Tudor Jones Sold Out
» More
Q1 2014

LGND Guru Trades in Q1 2014

Paul Tudor Jones 4,252 sh (New)
Steven Cohen 4,601 sh (New)
Joel Greenblatt Sold Out
RS Investment Management 1,222,507 sh (-7.04%)
» More
Q2 2014

LGND Guru Trades in Q2 2014

Jim Simons 38,594 sh (New)
Ken Fisher 36,908 sh (New)
Joel Greenblatt 55,492 sh (New)
RS Investment Management 1,392,185 sh (+13.88%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.04%$59.74 - $70.19 $ 50.07-23%55492
Ken Fisher 2014-06-30 New Buy$59.74 - $70.19 $ 50.07-23%36908
Joel Greenblatt 2014-03-31 Sold Out 0.02%$51.52 - $79.58 $ 50.07-25%0
Joel Greenblatt 2013-12-31 Add 124.95%0.01%$44.86 - $57.95 $ 50.07-4%13803
Joel Greenblatt 2013-09-30 New Buy0.01%$38.69 - $49.66 $ 50.0711%6136
Daniel Loeb 2011-12-31 Sold Out 0.46%$10.59 - $15.73 $ 50.07292%0
George Soros 2011-09-30 Sold Out 0.0017%$10.89 - $15.95 $ 50.07280%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 143.90
LGND's P/E(ttm) is ranked higher than
65% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. LGND: 143.90 )
LGND' s 10-Year P/E(ttm) Range
Min: 0.99   Max: 269.4
Current: 143.9

0.99
269.4
P/B 16.15
LGND's P/B is ranked lower than
51% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. LGND: 16.15 )
LGND' s 10-Year P/B Range
Min: 11.11   Max: 182
Current: 16.15

11.11
182
P/S 19.64
LGND's P/S is ranked higher than
53% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. LGND: 19.64 )
LGND' s 10-Year P/S Range
Min: 3.13   Max: 754
Current: 19.64

3.13
754
PFCF 60.33
LGND's PFCF is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LGND: 60.33 )
LGND' s 10-Year PFCF Range
Min: 49.17   Max: 425.29
Current: 60.33

49.17
425.29
EV-to-EBIT 63.94
LGND's EV-to-EBIT is ranked higher than
69% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. LGND: 63.94 )
LGND' s 10-Year EV-to-EBIT Range
Min: 53.4   Max: 2345.9
Current: 63.94

53.4
2345.9
Current Ratio 1.54
LGND's Current Ratio is ranked higher than
60% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. LGND: 1.54 )
LGND' s 10-Year Current Ratio Range
Min: 0.28   Max: 6.79
Current: 1.54

0.28
6.79
Quick Ratio 1.49
LGND's Quick Ratio is ranked higher than
67% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. LGND: 1.49 )
LGND' s 10-Year Quick Ratio Range
Min: 0.26   Max: 6.79
Current: 1.49

0.26
6.79

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.69
LGND's Price/Median PS Value is ranked higher than
62% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. LGND: 1.69 )
LGND' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 57.6
Current: 1.69

0.31
57.6
Earnings Yield (Greenblatt) 1.60
LGND's Earnings Yield (Greenblatt) is ranked higher than
56% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. LGND: 1.60 )
LGND' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.9
Current: 1.6

0.1
1.9
Forward Rate of Return (Yacktman) -0.91
LGND's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. LGND: -0.91 )
LGND' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.9   Max: 33.1
Current: -0.91

-13.9
33.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LGDN.Germany
Ligand Pharmaceuticals, Inc., is incorporated in Delaware. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. The Company has portfolio of over 80 current and future potential revenue generating programs, over 70 of which are fully funded by its partners. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSK's Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. In 2010, GSK received approval for Revolade (eltrombopag/Promacta) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and from the Japanese Ministry of Health, Labour and Welfare for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. In 2010, its partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. In 2006, Ligand outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, or Baxter (formerly Prism Pharmaceuticals, Inc.). In 2010, its partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. The Company currently has no manufacturing facilities and rely on third parties, including its collaborative partners, for clinical production of any products or compounds. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 

More From Our Partners
Why Lemelson Capital Is Short On Ligand Pharmaceuticals Oct 17 2014 - BENZINGA

More From Other Websites
Why Lemelson Capital Is Short On Ligand Pharmaceuticals Oct 17 2014
Tekmira Presents Data on Hepatitis B Candidate TKM-HBV Oct 16 2014
Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa Oct 16 2014
Insider Trading Alert - LGND, PANW And DK Traded By Insiders Oct 16 2014
Ligand to Host Analyst Day on November 18th in New York City Oct 16 2014
Ligand to Host Analyst Day on November 18th in New York City Oct 16 2014
MannKind (MNKD) Worth Watching: Stock Gains 12.9% Oct 16 2014
GW Pharmaceuticals Down on Disappointing Mid-Stage Data Oct 15 2014
Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition Oct 15 2014
Alnylam Reveals Positive Data from its Pipeline Candidates Oct 15 2014
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 8.5% Oct 15 2014
Momenta Pharmaceuticals (MNTA) in Focus: Stock Up 5.9% Oct 15 2014
Will Ligand Pharmaceuticals (LGND) Crush Estimates at Its Next Earnings Report? Oct 15 2014
Alnylam Jumps on Positive Patisiran Data from Phase II Study Oct 14 2014
Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx Oct 13 2014
Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% Oct 13 2014
Ligand Provides Better-than-Expected Q3 Earnings Guidance Oct 09 2014
Fed to the rescue…again! Oct 08 2014
Ligand Pharmaceuticals Inc. Shares Gain On Q3 Pre-Announcement Oct 08 2014
Ligand Reports Third Quarter Revenues and Expected Diluted EPS Oct 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK